Pharmacotherapies for renal cell carcinoma in Japan

摘要: The standard treatment for advanced renal cell carcinoma has changed dramatically in the past decade, from cytokine therapy to targeted therapy. Since sorafenib was approved April 2008, four tyrosine kinase inhibitors and two mammalian target of rapamycin have become available Japan. Most Japanese patients are treated by urologists who involved not only kidney surgeries, but also using inhibitors, as well inhibitors. Optimal methods selected theoretically-based global recommendations, such National Comprehensive Cancer Network European Society Medical Oncology guidelines; however, real-world clinical practice might be different that non-Asian countries. This because practical conditions; example, adverse events efficacy profiles, healthcare system, so on. In present review, we examine current pharmacotherapy evidence-based data, compare reality explore importance individualized patient